Literature DB >> 25694099

MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.

Michael R Marvin1, Nicole Ferguson, Robert M Cannon, Christopher M Jones, Guy N Brock.   

Abstract

Multiple studies have demonstrated an advantage for hepatocellular carcinoma (HCC) patients under the current liver allocation system, such that the United Network for Organ Sharing (UNOS) recently voted in support of a proposal to delay granting Model for End-Stage Liver Disease (MELD) exception points to all HCC patients for 6 months, independently of a candidate's native MELD score or alpha-fetoprotein (AFP) level. We obtained UNOS data on adult patients who were added to the wait list between January 22, 2005 and September 30, 2009, and we explored the relationship between HCC, MELD, AFP, and other factors that contribute to not only dropout on the wait list but posttransplant survival as well. The aim was to establish an equivalent Model for End-Stage Liver Disease (MELDEQ ) score for HCC patients that would reduce the disparity in access to transplantation between HCC and non-HCC patients. We determined risk groups for HCC patients with dropout hazards equivalent to those of non-HCC patients, and we evaluated projections for HCC wait-list dropout/transplantation probabilities on the basis of the MELDEQ prioritization scheme. Projections indicate that lower risk HCC patients (MELDEQ  ≤ 18) would have dropout probabilities similar to those of non-HCC patients in the same MELD score range, whereas dropout probabilities for higher risk HCC patients would actually be improved. The posttransplant survival of all HCC risk groups is lower than that of their non-HCC counterparts, with 1-year survival of 0.77 (95% CI, 0.70-0.85) for MELDEQ scores ≥ 31. These results suggest that HCC patients with a combination of a low biochemical MELD score and a low AFP level (MELDEQ  ≤ 15) would receive a marked advantage in comparison with patients with chemical MELD scores in a similar range and that a delay of 6 months for listing may be appropriate. In contrast, patients with MELDEQ scores > 15 would likely be adversely affected by a universal 6-month delay in listing.
© 2015 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25694099     DOI: 10.1002/lt.24098

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  8 in total

1.  Comparison of two equivalent model for end-stage liver disease scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry.

Authors:  Sarah K Alver; Douglas J Lorenz; Kenneth Washburn; Michael R Marvin; Guy N Brock
Journal:  Transpl Int       Date:  2017-08-23       Impact factor: 3.782

Review 2.  Transplantation for hepatocellular cancer: pushing to the limits?

Authors:  Quirino Lai; Alessandro Vitale
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-14

Review 3.  Advances in liver transplantation allocation systems.

Authors:  Michael L Schilsky; Maryam Moini
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

4.  Challenging the principle of utility as a barrier for wider use of liver transplantation for hepatocellular cancer.

Authors:  Michał Grąt; Jan Stypułkowski; Waldemar Patkowski; Karolina M Wronka; Emil Bik; Maciej Krasnodębski; Łukasz Masior; Zbigniew Lewandowski; Michał Wasilewicz; Karolina Grąt; Marek Krawczyk; Krzysztof Zieniewicz
Journal:  Ann Surg Oncol       Date:  2017-07-10       Impact factor: 5.344

5.  Incidental hepatocellular carcinoma after liver transplantation: Prevalence, histopathological features and prognostic impact.

Authors:  Pablo Pérez; Manuel Rodríguez-Perálvarez; Lourdes Guerrero; Víctor González; Rafael Sánchez; Macarena Centeno; Antonio Poyato; Javier Briceño; Marina Sánchez-Frías; Jose Luis Montero; Manuel De la Mata
Journal:  PLoS One       Date:  2017-04-12       Impact factor: 3.240

6.  Development of a Korean Liver Allocation System using Model for End Stage Liver Disease Scores: A Nationwide, Multicenter study.

Authors:  Juhan Lee; Jae Geun Lee; Inkyung Jung; Dong Jin Joo; Soon Il Kim; Myoung Soo Kim
Journal:  Sci Rep       Date:  2019-05-16       Impact factor: 4.379

Review 7.  The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?

Authors:  Xin Hu; Ronggao Chen; Qiang Wei; Xiao Xu
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

8.  Use of rapid Model for End-Stage Liver Disease (MELD) increases for liver transplant registrant prioritization after MELD-Na and Share 35, an evaluation using data from the United Network for Organ Sharing.

Authors:  Guy N Brock; Kenneth Washburn; Michael R Marvin
Journal:  PLoS One       Date:  2019-10-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.